Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 7/2021

Open Access 01-07-2021 | Parkinson's Disease | Review Article

Othello syndrome in Parkinson’s disease: a systematic review and report of a case series

Authors: Giovanna De Michele, Gianluigi Rosario Palmieri, Chiara Pane, Carmen Diletta Paola Dello Iacovo, Sandra Perillo, Francesco Saccà, Giuseppe De Michele, Anna De Rosa

Published in: Neurological Sciences | Issue 7/2021

Login to get access

Abstract

Introduction

Psychosis in Parkinson’s disease (PD) is common and consists of hallucinations, illusions, and delusions. Among the latter, delusional jealousy, also named Othello syndrome (OS), might impair the quality of life of both patients and their partners. We aimed to perform a systematic review and report a series of PD patients presenting with OS.

Methods

A systematic review research was performed in PubMed database, excluding non-English articles, single case reports, reviews and neuropathology articles, comments, and articles concerning OS associated with deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel infusion. We also described eleven PD patients (9 M and 2 F) with OS, identified in a cohort of consecutive 153 patients, comparing them with eleven matched no OS (nOS) PD subjects taken from the same cohort.

Results

We included eight articles (four case series and four cross-sectional studies). OS resulted more common among males than females. We did not find higher levodopa dose and levodopa equivalent dose for dopamine agonists and for all anti-parkinsonian drugs in our OS group. In our case series, OS patients showed visual hallucinations (p=0.001) and a trend to have depression (p=0.080) more frequently than nOS ones.

Conclusions

OS is not a rare disorder in PD, probably due not only to abnormal dopaminergic stimulation but also to serotonergic dysfunction in biologically predisposed subjects. Visual hallucinations and other concomitant psychiatric diseases, in particular depression, might represent a risk factor for the OS development.
Literature
1.
Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 13:2055e2066
2.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017) The psychosis spectrum in Parkinson disease. Nat Rev Neurol 13(2):81–95CrossRef
3.
Schneider RB, Iourinets J, Richard IH (2017) Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag 7(6):365–376CrossRef
4.
Warren N, O’Gorman C, Hume Z, Kisely S, Siskind D (2018) Delusions in Parkinson’s disease: a systematic review of published cases. Neuropsychol Rev 28(3):310–316CrossRef
5.
Kingham M, Gordon H (2004) Aspects of morbid jealousy. Adv Psychiatr Treat 10:207–215CrossRef
6.
Cipriani G, Vedovello M, Nuti A, di Fiorino A (2012) Dangerous passion: Othello syndrome and dementia. Psychiatry Clin Neurosci 66(6):467–473CrossRef
7.
Soyka M, Naber G, Völcker A (1991) Prevalence of delusional jealousy in different psychiatric disorders. An analysis of 93 cases. Br J Psychiatry 158:549–553CrossRef
8.
Poletti M, Perugi G, Logi C, Romano A, Del Dotto P, Ceravolo R, Rossi G, Pepe P, Dell’Osso L, Bonuccelli U (2012) Dopamine agonists and delusional jealousy in Parkinson’s disease: a cross-sectional prevalence study. Mov Disord 27(13):1679–1682CrossRef
9.
Perugi G, Poletti M, Logi C, Berti C, Romano A, Del Dotto P, Lucetti C, Ceravolo R, Dell’Osso L, Bonuccelli U (2013) Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia. Neurol Sci 34(9):1537–1541CrossRef
10.
Foley JA, Warner TT, Cipolotti L (2017) The neuropsychological profile of Othello syndrome in Parkinson’s disease. Cortex 96:158–160CrossRef
11.
Cannas A, Solla P, Floris G, Tacconi P, Marrosu F, Marrosu MG (2009) Othello syndrome in Parkinson disease patients without dementia. Neurologist 15(1):34–36CrossRef
12.
Solla P, Cannas A, Floris G, Orofino G, Costantino E, Boi A, Serra C, Marrosu MG, Marrosu F (2011) Behavioral, neuropsychiatric and cognitive disorders in Parkinson’s disease patients with and without motor complications. Prog Neuro-Psychopharmacol Biol Psychiatry 35(4):1009–1013CrossRef
13.
Kataoka H, Kiriyama T, Eura N, Sawa N, Ueno S, Sawa N, Ueno S (2014) Othello syndrome and chronic dopaminergic treatment in patients with Parkinson’s disease. Parkinsonism Relat Disord 20(3):337–339CrossRef
14.
Georgiev D, Danieli A, Ocepek L, Novak D, Zupancic-Kriznar N, Trost M, Pirtosek Z (2010) Othello syndrome in patients with Parkinson’s disease. Psychiatr Danub 22(1):94–98PubMed
15.
Graff-Radford J, Ahlskog JE, Bower JH, Josephs KA, James H, Bower JH, Keith A, Josephs KA (2010) Dopamine agonists and Othello’s syndrome. Parkinsonism Relat Disord 16(10):680–682CrossRef
16.
Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17CrossRef
17.
Graff-Radford J, Whitwell JL, Geda YE, Josephs KA (2012) Clinical and imaging features of Othello’s syndrome. Eur J Neurol 19(1):38–46CrossRef
18.
Watanabe H, Senda J, Kato S, Ito M, Atsuta N, Hara K, Tsuboi T, Katsuno M, Nakamura T, Hirayama M, Adachi H, Naganawa S, Sobue G (2013) Cortical and subcortical brain atrophy in Parkinson’s disease with visual hallucination. Mov Disord 28(12):1732–1736CrossRef
19.
Morgante L, Colosimo C, Antonini A, Marconi R, Meco G, Pederzoli M, Pontieri FE, Cicarelli G, Abbruzzese A, Zappulla S, Ramat S, Manfredi M, Bottacchi E, Abrignani M, Berardelli A, Cozzolino A, Paradiso C, De Gaspari D, Morgante F, Barone P, PRIAMO Study Group (2012) Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 83(1):76–82CrossRef
20.
Huot P, Fox SH (2013) The serotonergic system in motor and non-motor manifestations of Parkinson’s disease. Exp Brain Res 230(4):463–476CrossRef
21.
de la Riva P, Smith K, Xie SX, Weintraub D (2014) Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83(12):1096–1103CrossRef
22.
Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am Psychiatry 160(1):13–23CrossRef
23.
Figiel G, Sadowsky C (2008) A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 24(1):157–166CrossRef
24.
Factor SA, McDonald WM, Goldstein FC (2017) The role of neurotransmitters in the development of Parkinson’s disease-related psychosis. Eur J Neurol 24(10):1244–1255CrossRef
25.
Mäki-Marttunen V, Andreassen OA, Espeseth T (2020) The role of norepinephrine in the pathophysiology of schizophrenia. Neurosci Biobehav Rev 118:298–314CrossRef
26.
Espay AJ, LeWitt PA, Kaufmann H (2014) Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord 29(14):1710–1719CrossRef
27.
Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C (2020) The noradrenergic system in Parkinson’s disease. Front Pharmacol 8:435CrossRef
Metadata
Title
Othello syndrome in Parkinson’s disease: a systematic review and report of a case series
Authors
Giovanna De Michele
Gianluigi Rosario Palmieri
Chiara Pane
Carmen Diletta Paola Dello Iacovo
Sandra Perillo
Francesco Saccà
Giuseppe De Michele
Anna De Rosa
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 7/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05249-4

Other articles of this Issue 7/2021

Neurological Sciences 7/2021 Go to the issue

COVID-19

Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy

Brief Communication

Adult polyglucosan body disease—an atypical compound heterozygous with a novel GBE1 mutation

Letter to the Editor

Deep brain stimulation in Fragile X syndrome with tardive dystonia

Review Article

New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson’s disease

Letter to the Editor

Clinical characteristics of MOG antibody disease: two case reports

Letter to the Editor

Cerebellar dentate nuclei swelling: a new and early magnetic resonance imaging finding of beta-propeller protein–associated neurodegeneration